ArticleWorld journal of otorhinolaryngology - head and neck surgery2025
Integrative Analysis of Plasma Proteome and Genome Reveals Novel Drug Targets for Chronic Rhinosinusitis and Nasal Polyps.
Article in World journal of otorhinolaryngology - head and neck surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic rhinosinusitis (CRS) and nasal polyps (NP) are chronic inflammatory conditions with unsatisfactory treatment outcomes due to frequent recurrence of refractory disease. Identifying new therapeutic targets is essential. Methods: We conducted a proteome-wide Mendelian randomization (MR) analysis by integrating genome-wide association study genomic data of CRS/NP with cis-proteomic quantitative trait locus data to identify plasma proteins associated with CRS/NP risk. We validated the main findings using the Steiger test, Bayesian colocalisation, summary-data-based MR, and proteome-wide association studies. Single-cell expression analysis, enrichment analysis, protein-protein interaction networks, and drug availability assessments were performed to elucidate the functional pathways of the proteins and explore their potential as therapeutic targets for CRS/NP. Results: We identified nine proteins associated with the risk of NP and four proteins associated with the risk of CRS through proteome-wide MR analysis. Among these, three proteins (IL2RB, IL7R, and POR) associated with NP demonstrated the highest level of evidence and were prioritized. The protein-coding genes were primarily expressed in early secretory cells, tuft cells, ionocyte cells, basal cells, and secretory cells. These genes play significant roles in regulating the adaptive immune response and cytokine-cytokine receptor interaction. Four proteins (IL2RB, IL7R, POR, and TNFSF11) interacted with known drug targets for NP. Conclusions: Our study prioritizes IL2RB and IL7R as key mediators of CRS/NP pathogenesis via immune dysregulation. Their interactions with existing biologics underscore translational potential, offering mechanistic insights and actionable targets for biotherapy development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.